Written and Published FSI’s Development and Customer Engagement Teams – 801-785-7720
Left to right: (Development Team) Mel Poulsen, Kent Nielson, Daryn Cheney, (Customer Engagement Team) Ross Snyder – The FSI 411 guy
Release Information:
Delta version, November 01, 2022 update (Released November 02, 2022)
Medi-Span Drug Update.
Medi-Span (Wolters Kluwer) informs you of the following:
Wolters Kluwer would like to inform you about upcoming changes to two Prior Adverse Reaction (PAR) Classes that will occur on December 7, 2022, for weekly and monthly customers. These changes will be evident on January 4, 2023, for quarterly customers.
PAR Class 14 (Morphine and Related)
Fourteen KDCs that are not directly related to codeine and morphine will be removed from class membership (for example, hydrocodone, and oxycodone). From an allergy screening perspective, shared allergenic potential among these drugs has not been demonstrated. Removal of the drugs from PAR Class 14 (Morphine and Related) is expected to greatly decrease the volume of allergy alerts.
PAR Class 336 (Beta-2 Agonists)
This class will be retired, as shared allergenic potential among the majority of these drugs has not been demonstrated. From an allergy screening perspective, PAR Class 336 is not necessary.
FSI Point of Sale Software:
No Changes
FSI Pharmacy Management Software
No Changes
Download “FSI Client – Red Hat OpenJRE”
FSI-Client-21.002-Red-Hat-OpenJRE.msi – Downloaded 4022 times – 78.35 MB